Dove Barbanel
Lawyers
Filters
UCT acquisition of HIS Innovations Group
We advised UCT on the acquisition
DexCom $1.25 billion convertible notes offering and capped call transactions
The 0.375% convertible senior notes are due 2028
Revolution Medicines $345 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Natera $400 million follow-on offering
The shares are listed on Nasdaq